申请人:ACTELION PHARMACEUTICALS LTD.
公开号:US20160237088A1
公开(公告)日:2016-08-18
The invention relates to compounds of formula I
wherein “
” is a bond or is absent, V is CH, CR
6
or N; R
0
is H or, if “
” is a bond, may also be alkoxy; R
1
is H or halogen; U is CH or N when “
” is a bond, or, if “
” is absent, U is CH
2
, NH or NR
g
; R
2
is H, alkylcarbonyl or —CH
2
—R
3
; R
3
is H, alkyl or hydroxyalkyl; R
4
is H or, if n is not 0 and R
5
is H, may also be OH; R
5
is H, alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, carboxy or alkoxycarbonyl; R
6
is hydroxyalkyl, carboxy, alkoxycarbonyl or —(CH
2
)
q
—NR
7
R
8
, q being 1, 2 or 3 and each of R
7
and R
8
independently being H or alkyl or R
7
and R
8
forming with the N atom bearing them a ring; R
9
is alkyl or hydroxyalkyl; A is —(CH
2
)
p
—, —CH
2
CH
2
CH(OH)— or —COCH
2
CH(OH)—; G is substituted phenyl or G
1
or G
2
wherein Q is O or S and X is CH or N; and Y
1
, Y
2
and Y
3
may each be CH or N; and n is 0 when A is —CH
2
CH
2
CH(OH)— or —COCH
2
CH(OH)—, and n is 0, 1 or 2 when A is —(CH
2
)
p
—, p being 1, 2, 3 or 4, with the proviso that the sum of n and p is then 2, 3 or 4; and to salts thereof.
本发明涉及公式I的化合物,其中“”表示
化学键或不存在,V为CH、CR6或N;R0为H或,如果“”是
化学键,也可以是烷氧基;R1为H或卤素;当“”为
化学键时,U为CH或N,如果“”不存在,则U为
CH2、NH或NRg;R2为H、烷基羰基或— —R3;R3为H、烷基或羟基烷基;当n不为0且R5为H时,R4为H或也可以是OH;R5为H、烷基、羟基烷基、
氨基烷基、烷氧基烷基、羧基或烷氧羰基;R6为羟基烷基、羧基、烷氧羰基或—( )q—NR7R8,其中q为1、2或3,R7和R8各自独立地为H或烷基,或者R7和R8与它们所带的N原子形成一个环;R9为烷基或羟基烷基;A为—( )p—、— CH(OH)—或—CO CH(OH)—;G为取代苯基或G1或G2,其中Q为O或S,X为CH或N;Y1、Y2和Y3可以各自为CH或N;当A为— CH(OH)—或—CO CH(OH)—时,n为0,当A为—( )p—时,n为0、1或2,其中p为1、2、3或4,但总和n和p为2、3或4;以及其盐。